<DOC>
	<DOCNO>NCT00314873</DOCNO>
	<brief_summary>This study important demonstrate single agent activity note patient thymic tumor express c-kit and/or PDGF . If current trial positive , open door evaluate combination drug imatinib thymic tumor .</brief_summary>
	<brief_title>Pilot Study Imatinib ( Gleevec ) Treatment Advanced Thymic Carcinoma</brief_title>
	<detailed_description>Thymic carcinomas particularly concern due aggressive metastatic nature shorter overall survival , comparison lesser-malignant thymoma counterpart . This necessitate need systemic therapy . Due paucity thymic carcinoma case , ideal regimen locally advance metastatic thymic carcinoma defined.To point , study use imatinib thymic tumor express KIT tyrosine kinase protein PDGF tyrosine kinase protein . This study important demonstrate single agent activity note patient thymic tumor express c-kit and/or PDGF . If current trial positive , open door evaluate combination drug imatinib thymic tumor .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Histological cytological proof advance CKIT positive PDGFR positive thymic carcinoma . For protocol purpose , advance disease define disease Patient must least one document measurable lesion obtain image within 28 day prior register protocol therapy . No prior imatinib therapy . Age &gt; 18 year time consent ECOG performance status 0 1 ANC ≥ 1500/mm3 , Platelet count ≥ 100,000/mm , Total bilirubin &lt; 1.5ULN,3.10 Serum creatinine ≤ 1.7 mg/dl , ALT AST ≤ 3 x ULN Clinically significant infection judge treat investigator Clinically significant concurrent illness Females childbearing potential use birth control breastfeed Prior radiation therapy &gt; 25 % bone marrow Symptomatic brain metastasis History Grade III/IV cardiac problem History major surgery within 14 day prior register Treatment investigational agent within 30 day prior register protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Thymic malignancy</keyword>
	<keyword>Thymic Carcinoma</keyword>
</DOC>